Drag clinical

In performing pharmacogenomic studies in AD, it is necessary to rethink the therapeutic expectations of novel drags, redesign the protocols for drag clinical trials, and incorporate biological markers as assessable parameters of efficacy and... 

FIGURE 9.2 Histograms showing the number of new drag entities entering phase I clinical development (blue bars), and concomitantly the number entering phase III development as a function of year. Adapted from [2]. 

Capecitabine is used for the treatment of colorectal and breast cancers. It is contraindicated in patients with known hypersensitivity to capecitabine or any of its components or to 5-fluorouracil and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. The use of capecitabine is restricted in patients with severe renal impairment. The drag can induce diarrhea, sometimes severe. Other side effects include anemia, hand-foot syndrome, hyperbilirubinemia, nausea, stomatitis, pyrexia, edema, constipation, dyspnea, neutropenia, back pain, and headache. Cardiotoxicity has been observed with capecitabine. A clinically important drag interaction between capecitabine and warfarin has been demonstrated. Care should be exercised when the drag is co-administered with CYP2X9 substrates. 

Initial clinical trials with these new NNRTI drug candidates have provided the first in vivo evidence of their antiviral potency in both drag-naive (Herandez et al. 2000 Gruzdev et al. 2003) and NNRTI-experienced patients (Hammond et al. 2003 Wolfe et al. 2001 Gazzard et al. 2003). 

Several clinically used drags, e.g. salbirtamol (a/ -adrenoceptor agonist), propanol (a j3-adrenoceptor antagonist) and the 2-arylpropiotric acids (NSAIDs) are employed in... 

Pease JE, Horuk R. CCR1 antagonists in clinical development. Expert Opin Invest Drags 2005 14 785-796. 

---